Newsroom | 4785 results

Sorted by: Latest

Stem Cells
-

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on November 16, 2026, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award...
-

Nanoscope Therapeutics Partners with Uniphar to Expand Access to MOGENRY® Across the Gulf Cooperation Council Region

DALLAS & DUBLIN--(BUSINESS WIRE)--Nanoscope Therapeutics, Inc. (“Nanoscope”), a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that it has entered into an agreement with Uniphar, a global healthcare services partner to the pharmaceutical, biotech and medtech industries, under which Uniphar will serve as Nanoscope’s exclusive named patient s...
-

Signature Biologics alerta o público sobre o uso não autorizado do nome e da imagem do seu presidente, Dr. Neil Riordan

IRVING, Texas--(BUSINESS WIRE)--A Signature Biologics, LLC, desenvolvedora e fabricante de produtos celulares e biológicos sediada em Irving, alerta pacientes e o público em geral que empresas não afiliadas estão utilizando o nome, a fotografia e conteúdos em vídeo do seu fundador e presidente, Dr. Neil Riordan — sem o conhecimento ou consentimento dele ou da empresa, e de maneira falsa e enganosa — para promover seus próprios produtos e serviços à base de células-tronco. Essas empresas têm uti...
-

Signature Biologics advierte al público sobre el uso no autorizado del nombre y la imagen de su presidente, el Dr. Neil Riordan

IRVING, Texas--(BUSINESS WIRE)--Signature Biologics, LLC, empresa con sede en Irving dedicada al desarrollo y la fabricación de productos celulares y biológicos, advierte a los pacientes y al público en general que empresas sin vinculación con ella están utilizando el nombre, las fotografías y el contenido audiovisual de su fundador y presidente, el Dr. Neil Riordan, sin su conocimiento ni consentimiento, y de manera falsa y engañosa, para promocionar sus propios productos y servicios con célul...
-

Enterprise Therapeutics Granted EMA Orphan Medicinal Product Designation for Novel Cystic Fibrosis Therapy, ETD001

BRIGHTON, England--(BUSINESS WIRE)--Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted ETD001 designation as an orphan medicinal product for the treatment of cystic fibrosis. This follows the announcement earlier this year of a positive Phase 2...
-

VedaBio Demonstrates Under-10-Minute Molecular Detection with Target Amplification-Free CRISPR Technology at AMP 2026

SAN DIEGO--(BUSINESS WIRE)--VedaBio Demonstrates Under-10-Minute Molecular Detection with Target Amplification-Free CRISPR Technology at AMP 2026...
-

Enveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a comprehensive business update. CEO Commentary: “Our focus during the third quarter was advancing final IND-enabling activities for EB-003 as we prepare for the planned...
-

Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)--Q3 2026 Earnings Release...
-

Promega Enters License Agreement with BrainXell to Implement NanoLuc®, NanoBiT® and HaloTag® Technologies in iPSC-Derived Models

MADISON, Wis.--(BUSINESS WIRE)--Promega and BrainXell sign license to build HaloTag®, NanoLuc® and NanoBiT® reporter technologies into iPSC-derived neural models for research....
-

Takara Bio USA Collaborates with the Allen Institute to Enable Spatial Mapping Across Broader Brain Regions with the Trekker® Spatial Biology Platform

SAN JOSE, Calif.--(BUSINESS WIRE)--Takara Bio USA and Allen Institute enable spatial mapping across broader brain regions with an expanded version of the Trekker spatial platform....